New drug combinations to improve survival after radiation exposure
Official title: Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation
Funded at Bolder Biotechnology, INC. · NIH-10846717 · Data updated 2026-11-12
This study is looking at new combinations of drugs, including one called PEG IL-11, to see if they can help people who have been exposed to high levels of radiation and are experiencing acute radiation syndrome, especially when treatment starts 48 hours after exposure.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bolder Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Boulder, United States) |
| Project start | July 12, 2019 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $717,432 |
| NIH project number | 5R44AI142909-04 |
| Project ID | NIH-10846717 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who may be at risk of acute radiation syndrome due to exposure to radiation, such as in nuclear accidents or warfare.
✕Less likely to help
Patients who have not been exposed to high levels of radiation or those who are not at risk of acute radiation syndrome may not benefit from this research.
What this research studies
This research investigates the effectiveness of novel drug combinations in enhancing survival rates for patients suffering from acute radiation syndrome (H-ARS) when treatment is administered 48 hours after exposure to high levels of radiation. The study focuses on the use of a specific drug, PEG IL-11, and its combinations, which have shown promising results in animal models. By targeting the critical time window post-irradiation, the research aims to address a significant gap in current treatment options, as existing FDA-approved drugs are ineffective when administered after 24 hours. The approach involves testing these combinations in controlled environments to evaluate their potential benefits for human patients in future scenarios of radiation exposure.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly increases survival rates for individuals exposed to high doses of radiation.
How similar studies have gone: This research builds on previous findings that have shown success in animal models, but the approach of administering treatment 48 hours post-exposure is relatively novel and untested in humans.
Where this research is happening
-
Bolder Biotechnology, INC.
Boulder, United States Active
Researchers
- Principal investigator: Cox, George Norbert — Bolder Biotechnology, INC.
- Study coordinator: Cox, George Norbert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.